visualFeedback=off&questions=1&types=1,1,1,1,1,1&t1=The Phase I studies of ataluren established that&t2=D&t3=There was no protein elongation due to nonspecific ribosomal readthrough of normal stop codons&t4=Side effects were less common in patients on lower doses of ataluren&t5=The safety profile was acceptable and ataluren was palatable&t6=All of the above&t10=<B>Incorrect.</B>&t12=<B>Incorrect.</B>&t13=<B>Incorrect.</B>&t14=<B>Correct!</B>&